Brown Brothers Harriman & Co. Boosts Holdings in Novo Nordisk A/S (NYSE:NVO)

Brown Brothers Harriman & Co. boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 60.9% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 60,121 shares of the company's stock after acquiring an additional 22,754 shares during the period. Brown Brothers Harriman & Co.'s holdings in Novo Nordisk A/S were worth $5,172,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Daiwa Securities Group Inc. acquired a new stake in shares of Novo Nordisk A/S during the third quarter valued at about $28,000. Center for Financial Planning Inc. raised its position in Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after purchasing an additional 123 shares during the period. Dunhill Financial LLC lifted its stake in Novo Nordisk A/S by 196.8% during the third quarter. Dunhill Financial LLC now owns 469 shares of the company's stock worth $56,000 after purchasing an additional 311 shares in the last quarter. Albion Financial Group UT boosted its holdings in Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company's stock valued at $44,000 after acquiring an additional 278 shares during the period. Finally, Hager Investment Management Services LLC purchased a new position in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $46,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Price Performance

NYSE:NVO traded up $0.13 during trading hours on Wednesday, reaching $68.16. 3,140,395 shares of the company traded hands, compared to its average volume of 5,571,871. Novo Nordisk A/S has a 1-year low of $66.81 and a 1-year high of $148.15. The stock has a market cap of $305.89 billion, a P/E ratio of 20.70, a P/E/G ratio of 0.90 and a beta of 0.42. The firm's 50-day moving average is $81.89 and its 200-day moving average is $97.68. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Remove Ads

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S's dividend payout ratio is 47.72%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Morgan Stanley began coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. StockNews.com downgraded Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a report on Friday, March 21st. Stifel Nicolaus cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Finally, UBS Group upgraded Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.